294 1D09C3, a human, HLA-DR-specific monoclonal antibody efficiently induces programmed cell death in lymphoid tumors

Holz, Josefin-Beate; Nagy, Z A; Rattel, Benno; Lobenwein, Kurt; Leyer, Sigmar; Krenn, A.; Messemer, S.; Schwaiger, Franz-Werner

doi:10.1016/s1359-6349(04)80302-1

European Journal of Cancer Supplements

2004

DOI: 10.1016/s1359-6349(04)80302-1

|View full text |Cite

294 1D09C3, a human, HLA-DR-specific monoclonal antibody efficiently induces programmed cell death in lymphoid tumors

Josefin-Beate Holz¹,

Z A Nagy²,

Benno Rattel³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2006

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Emerging drugs for chronic lymphocytic leukaemia

Yee

O’Brien²

2006

Expert Opinion on Emerging Drugs

View full text Add to dashboard Cite

Although the philosophy of management of patients with chronic lymphocytic leukaemia (CLL) has been altered with the advent of fludarabine-based therapies, impact on long-term survival is unclear and a significant proportion of patients will develop resistance to fludarabine. Similar to other haematological malignancies, a potential for 'cure' is likely to be achieved only if 'high-quality' complete remissions (CRs) are achieved. Treatment options for patients who develop resistance to fludarabine continue to be limited, with only a proportion obtaining a response (usually not CRs) with salvage therapies. This review summarises novel therapies that are being evaluated in patients with CLL, specifically those targeting the antiapoptotic Bcl-2 family of proteins and receptors (e.g., CD40, CD80, HLA-DR) involved in mediating survival signals from the microenvironment.

show abstract

Emerging drugs for chronic lymphocytic leukaemia

Yee

O’Brien²

2006

Expert Opinion on Emerging Drugs

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

294 1D09C3, a human, HLA-DR-specific monoclonal antibody efficiently induces programmed cell death in lymphoid tumors

Cited by 1 publication

References 0 publications

Emerging drugs for chronic lymphocytic leukaemia

Emerging drugs for chronic lymphocytic leukaemia

Contact Info

Product

Resources

About